IonQ, Inc. Form 8-K Summary
Business Context and Reporting Period
IonQ, Inc. filed this Current Report on Form 8-K on December 9, 2022, reporting board changes occurring on December 5–8, 2022. The filing does not provide operating or financial results for a reporting period.
Key Financial and Capital Markets Information
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, guidance, or other operating metrics. It identifies IonQ’s common stock and warrants as listed on the New York Stock Exchange under the symbols IONQ and IONQ WS, respectively.
Material Changes
- Blake Byers resigned as a Class I director effective December 7, 2022.
- Dr. Byers served on the Audit Committee and the Nominating and Corporate Governance Committee. The filing states that his resignation was not due to any disagreement with the Company, management, or the Board.
- In connection with his resignation, the Board agreed to accelerate vesting of stock options and restricted stock units held by Dr. Byers. The filing does not provide the value or number of affected awards.
- Wendy Thomas was appointed as a Class I director effective December 8, 2022, filling the vacancy created by Dr. Byers. Her term expires at the 2025 Annual Meeting of Stockholders.
- Ms. Thomas was appointed to the Nominating and Corporate Governance Committee and was determined to be independent under NYSE rules and applicable regulations.
Compensation, Outlook, and Risks
Under IonQ’s Non-Employee Director Compensation Policy, Ms. Thomas will receive an annual Board retainer of $30,000 and an annual Nominating and Corporate Governance Committee retainer of $4,000. She will also receive an initial equity award with a stated dollar-denominated value of $400,000, consisting of restricted stock units and a stock option, each vesting over three years with one-third vesting annually, subject to continued board service.
Ms. Thomas entered into the Company’s standard indemnification agreement. The filing identifies no arrangement or understanding related to her selection, no family relationship with IonQ directors or executive officers, and no related-party transaction reportable under Item 404(a) of Regulation S-K. No management guidance, outlook, contingencies, or unusual operating risks are discussed.
Investor Verification Items
- Verify the number and financial impact of the accelerated awards granted to Dr. Byers.
- Review the terms and grant-date value of Ms. Thomas’s $400,000 initial equity award.
- Confirm the resulting composition and committee assignments of IonQ’s Board.
- Review subsequent filings for any additional compensation, governance, or board changes.